ReviewPloS one2025
A re-evaluation study and literature review on AD8 as a screening tool for dementia.
Review in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- The Impact of Augmented Reality-Based Aromatherapy Education on Symptoms in Older Adults with Early-Stage Dementia.Healthcare (Basel, Switzerland) · 2026Article
- Article
- The mediating role of coping style in the relationship between optimism and cognitive impairment in patients with stroke.Frontiers in neurology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe Eight-Item Informant Interview to Differentiate Aging and Dementia (AD8) was developed as a screening tool for dementia, with a cutoff score of 2 suggested by the initial study. However, various studies have reported different cutoff values, and many have found that a cutoff of 2 may result in a high false positive rate. Furthermore, a high false positive rate has repeatedly been shown when the AD8 is self-administered in local government screening programs in Taiwan.
objectivesThis study aimed to test the AD8's performance, define its best cutoff value, review factors that may affect its performance, and reconsider its role in clinical practice.
methodsWe recruited 118 participant-informant dyads from a university teaching hospital. For each informant, the AD8 was administered before the Clinical Dementia Rating (CDR) to minimize recall bias. Two geriatric psychiatrists made a consensus clinical diagnosis for each participant based on the DSM-5 criteria. Receiver operating characteristic analysis was used to assess the performance of the AD8.
resultsThirty-seven participants had a CDR of 0, 61 had a CDR of 0.5, and 20 had a CDR ≥ 1. To discriminate between the participants with CDR 0 and those with CDR 0.5, the optimal cutoff score for the AD8 was 2. Including those with CDR ≥ 1 changed the best cutoff value to 3. In terms of the DSM-5 criteria, 59 participants had normal cognition, 28 had mild neurocognitive disorder, and 31 had major neurocognitive disorder or dementia. To discriminate between those with and without dementia, an AD8 cutoff value of 4 maximized the Youden index with more balanced sensitivity and specificity.
conclusionThe AD8 may have different cutoff values depending on different purposes. Our findings suggest that the AD8 may perform better with a cutoff value of 4 to discriminate between those with and without dementia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.